Pharmaceutical Executive
June 01, 2011
Issue PDF
0
0
Emerging Pharma Leaders 2011
June 01, 2011
Columns
0
0
FDA's opiod REMS implies there is still value in industry-sponsored CME
June 01, 2011
Columns
0
0
The payoff is superior performance in key areas such as clinical trials
June 01, 2011
0
0
Carefully crafting your brand's positioning could ensure that you'll not just win the sprint, but also the marathon
June 01, 2011
Features
0
0
With Yankee stadium as the backdrop, Pharm Exec convened its annual panel of eight business development experts to crack the bat on best practice in licensing and M&A for the year ahead.
June 01, 2011
0
0
NicVAX is trying to buck the trend of smoking-cessation products' high failure rate
June 01, 2011
0
0
Pharma company communicators must steer the conversation about vaccines to the ultimate goal-preventing disease
June 01, 2011
Columns
0
0
Why has the EU still not managed to update its rules on information about medicines?
June 01, 2011
Columns
0
0
NeHC's new Consumer Consortium is promoting a new stakeholder agenda to improve patient knowledge
June 01, 2011
0
0
Creating and managing expectations is the most basic rule of marketing
June 01, 2011
Columns
0
0
Successful negotiations require a willingness to take risks and an ability to adapt
June 01, 2011
Columns
0
0
Patent expiries are inevitable, but brand teams should look to graduate the sales curve
June 01, 2011
Columns
0
0
What do our genetics tell us about our predisposition to certain diseases?
June 01, 2011
0
0
A vaccination against addiction could open up a whole new category
June 01, 2011
0
0
To decide on a course of treatment, patients need to be told the truth straight up
June 01, 2011
0
0
With a first-in-class compound marketers can potentially leverage long-lasting market advantages
June 01, 2011
0
0
Suggestions for testing new ways of addressing difficult issues of risk